Final results of 2-dose fractionation of 177mLu-J591 for progressive metastatic castration-resistant prostate cancer mCRPC).

被引：8
|
作者：
Tagawa, Scott T.
Batra, Jaspreet
Vallabhajosula, Shankar
Jhanwar, Yuliya
Christos, Paul J.
Emmerich, Lauren
Karir, Beerinder S.
Karpenko, Irene
Lam, Linda
Febles, Victor R. A.
Molina, Ana M.
Beltran, Himisha
Goldsmith, Stanley J.
Bander, Neil Harrison
Nanus, David M.
机构：
[1] Weill Cornell Med, New York, NY USA
[2] Weill Cornell Med Coll, New York, NY USA
[3] Weill Cornell Med, New York Presbyterian Hosp, New York, NY USA
[4] New York Presbyterian Hosp Cornell, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.5022
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5022
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Cabazitaxel for octogenarian patients with metastatic castration-resistant prostate cancer (MCRPC)
    Tralongo, P.
    Bordonaro, S.
    Di Lorenzo, G.
    Borsellino, N.
    Facchini, G.
    Rossetti, S.
    Martelli, V.
    Longo, V.
    Tralongo, A. C.
    Caspani, F.
    Tuzi, A.
    Spada, M.
    Calvani, N.
    Carlini, P.
    De Giorgi, U. F. F.
    ANNALS OF ONCOLOGY, 2019, 30
  • [22] Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
    Karunaratna, Nathasha
    Jensen, Andrew
    Wong, Shirley
    Shapiro, Julia
    Weickhardt, Andrew
    Spain, Lavinia
    Azad, Arun
    Kwan, Edmond M.
    Muthusamy, Arun
    Torres, Javier
    Parente, Phillip
    Parnis, Francis
    Goh, Jeffrey
    Gibbs, Peter
    Tran, Ben
    Anton, Angelyn
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 58 - 58
  • [23] Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Henriquez, Ivan
    Roach, Mack I. I. I. I. I. I.
    Morgan, Todd M.
    Bossi, Alberto
    Gomez, Junior A.
    Abuchaibe, Oscar
    Counago, Felipe
    BIOMEDICINES, 2021, 9 (09)
  • [24] Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC)
    Morris, Michael J.
    Pandit-Taskar, Neeta
    Carrasquillo, Jorge A.
    O'Donoghue, Joseph A.
    Humm, John
    Lyashchenko, Serge K.
    Haupt, Eric C.
    Bander, Neil Harrison
    Tagawa, Scott T.
    Holland, Jason P.
    Smith-Jones, Peter M.
    Lewis, Jason Stuart
    Solomon, Stephen Barnett
    Scher, Howard I.
    Larson, Steven M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [25] Results of phase 2 study of [177Lu]Ludotadipep for metastatic castration-resistant prostate cancer
    Kwon, S.
    Lee, J.
    Park, C.
    Min, J.
    Ha, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S328 - S328
  • [26] VISION trial: 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer
    Rohith, Gorrepati
    INDIAN JOURNAL OF UROLOGY, 2021, 37 (04) : 372 - 373
  • [27] ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC)
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Maneval, Edna Chow
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [28] Combining molecular and functional imaging in metastatic castration-resistant prostate cancer (mCRPC).
    Conteduca, Vincenza
    Scarpi, Emanuela
    Wetterskog, Daniel
    Caroli, Paola
    Romanel, Alessandro
    Lolli, Cristian
    Jayaram, Anuradha
    Gurioli, Giorgia
    Brighi, Nicole
    Poti, Giulia
    Wingate, Anna
    Schepisi, Giuseppe
    Matteucci, Federica
    Paganelli, Giovanni
    Demichelis, Francesca
    Attard, Gerhardt
    De Giorgi, Ugo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [29] Modulation of plasma lipidomic signature in metastatic castration-resistant prostate cancer (mCRPC).
    Mak, Blossom
    Mahon, Kate Lynette
    Stockler, Martin R.
    Joshua, Anthony M.
    Zhang, Alison Yan
    Parnis, Francis
    Meikle, Peter
    Horvath, Lisa
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [30] Pembrolizumab in men with heavily treated metastatic castration-resistant prostate cancer (mCRPC).
    Tucker, Matthew D.
    Zhu, Jason
    Berry, William R.
    Ramalingam, Sundhar
    Zhang, Tian
    Harrison, Michael Roger
    Wu, Yuan
    Healy, Patrick
    George, Daniel J.
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
12345